Abstract
Arterial hypertension is a progressive cardiovascular syndrome arising from complex and interrelated etiologies. The human microbiome refers to the community of microorganisms that live in or on the human body. They influence human physiology by interfering in several processes such as providing nutrients and vitamins in Phase I and Phase II drug metabolism. The human gut microbiota is represented mainly by Firmicutes and Bacteroidetes and to a lesser degree by Actinobacteria and Proteobacteria, with each individual harbouring at least 160 such species. Gut microbiota contributes to blood pressure homeostasis and the pathogenesis of arterial hypertension through production, modification, and degradation of a variety of microbial-derived bioactive metabolites. Animal studies and to a lesser degree human research has unmasked relative mechanisms, mainly through the effect of certain microbiome metabolites and their receptors, outlining this relationship. Interventions to utilize these pathways, with probiotics, prebiotics, antibiotics and fecal microbiome transplantation have shown promising results. Personalized microbiome-based disease prediction and treatment responsiveness seem futuristic. Undoubtedly, a long way of experimental and clinical research should be pursued to elucidate this novel, intriguing and very promising horizon.
Keywords: Gut microbiome, gut flora, microorganisms, arterial hypertension, short chain fatty acids, probiotics, prebiotics.
Graphical Abstract
[1]
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation 2016; 133(4): e38-e360.
[2]
Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the US: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013; 133: 1-8.
[3]
Yoon SS, Gu Q, Nwankwo T, Wright JD, Hong Y, Burt V. Trends in blood pressure among adults with hypertension: the United States, 2003 to 2012. Hypertension 2015; 65(1): 54-61.
[4]
Giles TD, Materson BJ, Cohn JN, Kostis JB. Definition and classification of hypertension: An update. J Clin Hypertens (Greenwich) 2009; 11(11): 611-4.
[5]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014; 23(1): 3-16.
[6]
Beevers G, Lip GYH, O’Brien E. ABC of hypertension - The pathophysiology of hypertension. BMJ 2001; 322(7291): 912-6.
[7]
McCormack T, Krause T, O’Flynn N. Management of hypertension in adults in primary care: A NICE guideline. Br J Gen Pract 2012; 62(596): 163-4.
[8]
James PA, Oparil S, Carter BL. 2014 evidence-based guideline for the management of high blood pressure in adults: A report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.
[9]
Foëx P, Sear JW. Hypertension: Pathophysiology and treatment. Contin Educ Anaesth Crit Care Pain 2004; 4(3): 71-5.
[10]
Delacroix S, Chokka RC, Worthley SG. Hypertension: Pathophysiology and treatment. J Neurol Neurophysiol 2014; 5: 250.
[11]
Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res 2015; 116(6): 937-59.
[12]
Morris BJ. Renin, genes, microRNAs, and renal mechanisms involved in hypertension. Hypertension 2015; 65(5): 956-62.
[13]
Honour JW. Historical perspective: Gut dysbiosis and hypertension. Physiol Genomics 2015; 47(10): 443-6.
[14]
Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens 2015; 24(5): 403-9.
[15]
Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464(7285): 59-65.
[16]
Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol 2013; 14: 676-84.
[17]
Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc 2003; 62: 67-72.
[18]
Hoverstad T, Midtvedt T. Short-chain fatty acids in germfree mice and rats. J Nutr 1986; 116: 1772-6.
[19]
Pevsner-Fischer M, Blacher E, Tatirovsky E, Ben-Dov IZ, Elinav E. The gut microbiome and hypertension. Curr Opin Nephrol Hypertens 2017; 26(1): 1-8.
[20]
Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461: 1282-6.
[21]
Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122: 107-18.
[22]
Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-23.
[23]
Segain JP, Raingeard de la Bletiere D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut 2000; 47: 397-403.
[24]
Mortensen FV, Nielsen H, Mulvany MJ, Hessov I. Short chain fatty acids dilate isolated human colonic resistance arteries. Gut 1990; 31: 1391-4.
[25]
Nutting CW, Islam S, Daugirdas JT. Vasorelaxant effects of short chain fatty acid salts in rat caudal artery. Am J Physiol 1991; 261(2 Pt 2): H561-7.
[26]
Pluznick JL. Renal and cardiovascular sensory receptors and blood pressure regulation. Am J Physiol Renal Physiol 2013; 305: F439-44.
[27]
Pluznick JL, Zou DJ, Zhang X, et al. Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA 2009; 106: 2059-64.
[28]
Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 2013; 110: 4410-5.
[29]
Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278: 25481-9.
[30]
Keshaviah PR. The role of acetate in the etiology of symptomatic hypotension. Artif Organs 1982; 6: 378-87.
[31]
Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278: 11312-9.
[32]
Mell B, Jala VR, Mathew AV, et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics 2015; 47: 187-97.
[33]
Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 1975; 36: 692-6.
[34]
Elijovich F, Weinberger MH, Anderson CA. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension 2016; 68: e7-e46.
[35]
Kristev A, Mitkov D, Lukanov J. Influence of short-chain fatty acids on vascular tone. Int J Exp Pathol 1991; 72: 475-80.
[36]
Yang T, Santisteban MM, Rodriguez V, et al. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65: 1331-40.
[37]
Aoki K, Yamori Y, Ooshima A, Okamoto K. Effects of high or low sodium intake in spontaneously hypertensive rats. Jpn Circ J 1972; 36: 539-45.
[38]
Durgan DJ, Bryan RM Jr. Cerebrovascular consequences of obstructive sleep apnea. J Am Heart Assoc 2012; 1: e000091.
[39]
Quan SF, Howard BV, Iber C, et al. The sleep heart health study: Design, rationale, and methods. Sleep 1997; 20: 1077-85.
[40]
Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829-36.
[41]
Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479-82.
[42]
Durgan DJ, Ganesh BP, Cope JL, et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 2016; 67: 469-74.
[43]
Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575-84.
[44]
Bomfim GF, Dos Santos RA, Oliveira MA, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond) 2012; 122: 535-43.
[45]
Bomfim GF, Echem C, Martins CB, et al. Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sci 2015; 122: 1-7.
[46]
McCarthy CG, Wenceslau CF, Goulopoulou S, et al. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res 2015; 107: 119-30.
[47]
Desvarieux M, Demmer RT, Jacobs DR, et al. Periodontal bacteria and hypertension: the oral infections and vascular disease epidemiology study (INVEST). J Hypertens 2010; 28: 1413-21.
[48]
Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288: 1882-8.
[49]
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-24.
[50]
Nakamura Y, Masuda O, Takano T. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem 1996; 60: 488-9.
[51]
Fuglsang A, Rattray FP, Nilsson D, Nyborg NC. Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo. Antonie van Leeuwenhoek 2003; 83: 27-34.
[52]
Liu CF, Tung YT, Wu CL, et al. Antihypertensive effects of Lactobacillus fermented milk orally administered to spontaneously hypertensive rats. J Agric Food Chem 2011; 59: 4537-43.
[53]
Beltran-Barrientos LM, Hernandez-Mendoza A, Torres-Llanez MJ, et al. Invited review: fermented milk as antihypertensive functional food. J Dairy Sci 2016; 99: 4099-110.
[54]
Nakamura Y, Yamamoto N, Sakai K, et al. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 1995; 78: 777-83.
[55]
Masuda O, Nakamura Y, Takano T. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 1996; 126: 3063-8.
[56]
Hata Y, Yamamoto M, Ohni M, et al. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996; 64: 767-71.
[57]
Aihara K, Kajimoto O, Hirata H, et al. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 2005; 24: 257-65.
[58]
Upadrasta A, Madempudi RS. Probiotics and blood pressure: Current insights. Integr Blood Press Control 2016; 9: 33-42.
[59]
Robles-Vera I, Toral M, Romero M, et al. Antihypertensive effects of probiotics. Curr Hypertens Rep 2017; 19(4): 26.
[60]
AbuMweis SS, Jew S, Ames NP. B-Glucan from barley and its lipid-lowering capacity: A meta-analysis of randomized, controlled trials. Eur J Clin Nutr 2010; 64: 1472-80.
[61]
Maki KC, Beiseigel JM, Jonnalagadda SS, et al. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. J Am Diet Assoc 2010; 110: 205-14.
[62]
Braaten JT, Wood PJ, Scott FW, et al. Oat gum lowers glucose and insulin after an oral glucose load. Am J Clin Nutr 1991; 53: 1425-30.
[63]
Wang Y, Ames NP, Tun HM, et al. High molecular weight barley beta-glucan alters gut microbiota toward reduced cardiovascular disease risk. Front Microbiol 2016; 7: 129.
[64]
Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31.
[65]
Kemppainen KM, Ardissone AN, Davis-Richardson AG, et al. Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes. Diabetes Care 2015; 38: 329-32.
[66]
Ahn J, Sinha R, Pei Z, Dominianni C, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105: 1907-11.
[67]
Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: A randomized controlled trial. Gastroenterology 2002; 123: 33-40.
[68]
Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330: 831-5.
[69]
Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 2013; 341: 295-8.
Related Books
Blood Oxidant Ties: The Evolving Concepts in Myocardial Injury and Cardiovascular Disease
Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives
Herbal Medicine: Back to the Future
Cardiac Care and COVID-19: Perspectives in Medical Practice
Nanomedicinal Approaches Towards Cardiovascular Disease
Herbal Medicine: Back to the Future
Article Metrics
75
3